The early-access programs
France's Forfait Innovation: coverage-with-evidence-development for breakthrough devices — the 2026 SAPIEN M3 proof point.
Free field guide · PDF
EU Device Reimbursement2026 Field Guide
The early-access programs, the innovation doors, and the payers' logic — with the EU practice you need.
- Core rule
- CE≠paid
- Forfait Inn.
- 2015
- Germany
- NUB
Sourced from verified 2026 publications.
Download the free guide
Enter your work email and we'll send the PDF straight to your inbox.
What's inside
Five pages, zero fluff
Every figure in this guide traces to a named source — verified 2026 publications.
The innovation doors
Germany's NUB, France's LATM and PECAN, the UK's triple gate: CE/UKCA, DTAC, and NICE.
The payers' logic
CE marking authorises placement, not payment — national HTA decisions and the parallel-discipline logic of market access.
Sources & scope
- mtrconsult.com, Forfait Innovation favorable opinion (SAPIEN M3, Sep 2026).
- mtrconsult.com, The application period for the 2026 NUB innovation funding is open in Germany.
- iclg.com, Evolution of Digital Health Reimbursement (US, Germany, UK, France).
This guide is market-access intelligence, not regulatory, reimbursement, or legal advice. EU reimbursement programs, HTA criteria, and payer rules change — professional review is required before business use.
Market Access Strategy Session
EU reimbursement on your 2026 roadmap? Start with the full picture.
A Market Access Strategy Session maps your reimbursement route — HTA positioning, innovation-door strategy, and payer evidence.
Professional review is required before business use.
Back to ghmap.io Questions? Talk to our team